Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471461 | 0.79 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL15144965 | 0.77 | PORCN (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL2370406 | 0.77 | MTOR (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL2369667 | 0.74 | MTOR (0.55) | — | |
| SCHEMBL8533161 | 0.74 | AGTR2 (0.43) | AGTR2HCRTR1HCRTR2 | |
| SCHEMBL2369920 | 0.73 | MTOR (0.48) | — | |
| SCHEMBL2369911 | 0.73 | MTOR (0.48) | — | |
| SCHEMBL2370567 | 0.72 | MTOR (0.56) | — | |
| SCHEMBL2369988 | 0.71 | MTOR (0.56) | — | |
| SCHEMBL22917166 | 0.70 | AGTR2 (0.70) | AGTR2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | AGTR2 3149/4885HCRTR1 3325/4885HCRTR2 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.